Abstract: OBJECTIVE To understand the distribution and drug resistance of the pathogens isolated from the patients of outpatient department. METHODS According to the programs of China Antimicrobial Resistance Surveillance System (CARSS), the data of isolated pathogens and results of drug susceptibility testing that were reported by members of CARSS in 2021 were analyzed by using WHONET 5.6 software. RESULTS A total of 95 599 strains of pathogens were isolated from the patients of outpatient department in 2021. Escherichia coli and Klebsiella pneumoniae were dominant among gram-negative bacteria; Staphylococcus aureus and Streptococcus agalactiae were the predominant species of gram-positive bacteria. The isolation rates of methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococcus were 24.0% and 68.0%, respectively; no strains that were resistant to vancomycin, teicoplanin or linezolid were found. The drug resistance rates of Enterococcus faecalis strains were lower than those of Enterococcus faecium to most of the antibiotics, and both of the species were resistant to vancomycin. The drug resistance rate of the Streptococcus pneumoniae strains isolated from non-cerebrospinal fluid specimens to penicillin was 0.6%. The drug resistance rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains to carbapenems were 10.9% and 39.6%, respectively. The average drug resistance rates of Escherichia coli and Klebsiella pneumoniae strains to ceftriaxone/cefotaxime were 44.8% and 28.4%, respectively. The drug resistance rates of Enterobacteriaceae strains to 3 types of carbapenems ranged between 0.4% and 7.2%; the isolation rates of carbapenem-resistant E.coli and carbapenem-resistant K.pneumoniae were 0.9% and 6.8%, respectively. The drug resistance rate of the Haemophilus influenzae strains to ampicillin was 60.7%. CONCLUSION The pathogens isolated from the outpatient department patients are highly drug-resistant in 2021. It is necessary to continuously strengthen the surveillance of antimicrobial resistance so as to facilitate the reasonable use of antibiotics.